LUMIRABIO at the 94th API China: From Peptide Interest to Project Qualification

The 94th API China in Shanghai

The 94th China International Pharmaceutical Ingredients, Intermediates, Packaging and Equipment Fair, widely known as API China, was held from May 13 to 15, 2026, at the National Exhibition and Convention Center in Shanghai.

It ran alongside the 92nd PHARMCHINA and the 2026 China International Natural Health and Nutrition Expo.

LUMIRABIO's original event recap, citing organizer materials for the combined exhibitions, reported approximately 170,000 square metres and more than 3,000 participating pharmaceutical and health-industry companies.

API China's official materials describe a platform spanning pharmaceutical R&D, production and supply-chain resources, including quality control, production processes and regulatory compliance.

What LUMIRABIO presented

Our display covered peptide raw-material programs and formulation-development topics, including semaglutide, tirzepatide and retatrutide.

A peptide material, API, development candidate and finished dosage form occupy different technical and regulatory categories, so the exact category and use are defined in each project.

LUMIRABIO supports peptide work across R&D, synthesis, purification, lyophilization and quality testing.

For priority programs, we manage mature synthesis processes, impurity control, batch-to-batch consistency, stable production and supply planning against defined requirements.

Peptides can offer high receptor selectivity and substantial design flexibility depending on sequence, modification and formulation.

Oral delivery, safety, stability and manufacturability remain molecule-specific rather than universal class properties.

Why a peptide project requires more than a molecule name

A technically meaningful discussion goes beyond nominal identity or headline purity.

It may include sequence confirmation, material form and counter-ion, related substances, residual solvents, water, analytical methods, stability, packaging, storage and change control.

Our connected workflow links synthesis, purification, lyophilization and quality testing so these questions can be reviewed together.

Claims about impurity control, batch consistency and supply are evaluated against the exact product, specification, method and project requirement.

Semaglutide and tirzepatide are active ingredients in approved finished medicines in defined markets and indications.

Retatrutide remains investigational.

Product-specific use, site, entity, documentation, target market and intellectual-property position remain part of qualification.

Professional exchange and preliminary cooperation

Throughout the exhibition, our team met distributors, pharmaceutical company representatives, enterprise institutions and research specialists from across China and the wider industry.

Discussions covered product requirements, development work, quality expectations, production and supply, market needs and potential cooperation.

The event produced multiple company-reported preliminary cooperation intentions and practical follow-up opportunities.

These discussions now move into technical definition, confidentiality, quality review and commercial qualification before any formal commitment.

The exchange also sharpened our view of buyer expectations and product presentation, supporting continued optimization of technical communication and market strategy.

Questions CMC, quality and procurement teams should ask

After an exhibition, a qualified supplier discussion should move toward evidence and responsibility.

Useful questions include:

• Is the material a research material, intermediate, API, formulation input or finished product?
• Which legal entity manufactures, releases and supplies it?
• What specification and analytical methods apply?
• How are identity, purity, related substances, counter-ion, water and residual solvents addressed?
• What batch, traceability, stability and packaging information can be reviewed?
• Which documents are public, inquiry-gated, NDA-gated or audit-room only?
• What target-market, intellectual-property, regulatory and import constraints apply?
• How will changes, deviations, complaints and supply continuity be handled?

The work starts after the exhibition

API China provided a strong setting for technical exchange, product discussion and business follow-up.

The next step is to move from general interest to a documented qualification process.

Pharmaceutical, biotechnology, CMC, quality and procurement teams can continue the discussion with a molecule, material form, intended use, target market, specification, estimated quantity and required documents.

LUMIRABIO uses that information to define technical, quality, production and supply scope.